TMDI - TMDI STOCK NEWS

Titan Medical Inc. (Nasdaq: TMDI) announced it will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investment Hybrid Conference from September 12-14, 2022, in New York and virtually. CEO Cary Vance, CFO Stephen Lemieux, and VP Kristen Galfetti will represent the company. The presentation will be available on-demand on September 12 at 7:00 am ET on the company's Investor Relations webpage. Titan aims to enhance robotic-assisted surgery, primarily targeting gynecologic indications with the Enos system.

Titan Medical Inc. (TMDI) announced the appointment of Cary G. Vance as President and CEO, emphasizing progress in developing its Enos™ single access robotic-assisted surgery system. The company plans to submit an Investigational Device Exemption (IDE) application to the FDA by mid-2023, targeting benign gynecologic surgeries. Financially, Titan reported $20.2 million in cash as of June 30, 2022, down from $32.3 million at year-end 2021. R&D expenses increased to $9.5 million amid ongoing development efforts, while G&A expenses decreased to $3.1 million.

Titan Medical Inc. (TMDI) announced its plans to release Q2 2022 financial results before market opening on August 11, 2022. An investor audio webcast will follow at 8:30 a.m. ET, featuring key executives discussing the results and business developments. Titan Medical focuses on single access robotic-assisted surgery, developing the Enos™ system aimed to enhance surgical capabilities, particularly in gynecological procedures. The company emphasizes innovative technology and ergonomic design to improve surgical outcomes.

Titan Medical Inc. (Nasdaq: TMDI) has announced Cary G. Vance as its new President and CEO, effective July 1, 2022, succeeding Paul Cataford, who served as Interim President and CEO since December 2021. Vance brings extensive leadership experience from positions at Xcath and Hansen Medical, among others. Cataford will remain as board chair, while Vance is expected to leverage his familiarity with Titan’s technology to drive commercialization efforts, particularly in robotic-assisted surgery.

Titan Medical Inc. (Nasdaq: TMDI) received a notification from Nasdaq granting an additional 180 days, until December 26, 2022, to meet the minimum bid price requirement of US$1.00 for continued listing. The company must close at or above this price for 10 consecutive business days to regain compliance. Failure to comply may lead to delisting, although appeals could be made. This notification does not affect the company's status on the Toronto Stock Exchange. Titan Medical specializes in robotic-assisted surgery and is developing its Enos™ surgical system for gynecologic procedures.

Titan Medical Inc. (Nasdaq: TMDI) announced a revised timeline for its Enos™ robotic surgery system due to multiple disruptions. The Investigational Device Exemption (IDE) submission is now expected in mid-2023, delayed from Q1 2023. Despite these delays, the U.S. product launch remains on track for early 2025. Key issues include supply chain disruptions, software recruitment challenges, and delays in component procurement. The company maintains confidence in its project team and plans to initiate clinical trials in 2023.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) announced participation in the Society of Robotic Surgery Annual Meeting from June 30 to July 3, 2022, in Orlando, Florida. Vice President Chris Seibert will participate in a panel on emerging robotic platforms and present the company's vision during the plenary session. Titan aims to lead in robotic-assisted surgery with its Enos™ single access surgical system, designed for gynecologic procedures. Seibert emphasized the opportunity to showcase Titan's innovations to clinical experts.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) has announced a partnership with Nissha Medical Technologies for manufacturing surgical consumables required for the verification and validation testing of its Enos™ robotic surgical system. This agreement aims to enhance the development of single-access robotic-assisted surgery. The collaboration is expected to facilitate pre-clinical and clinical studies. The Enos system focuses on improving surgical ergonomics and capabilities, targeting gynecologic applications.

Titan Medical Inc. (Nasdaq: TMDI) reported the results of its Annual and Special Meeting held on June 8, 2022. Shareholders elected all management nominees as directors, with 54,760,905 shares voted (49.24% of total). The company approved the appointment of BDO Canada LLP as independent auditors, and renewed both the company’s share unit plan and deferred share unit plan. A new employee share purchase plan was also approved. Titan Medical focuses on innovative surgical technologies, particularly the Enos™ robotic system for single access robotic-assisted surgery.